WO2011057267A1 - Vaccine composition - Google Patents
Vaccine composition Download PDFInfo
- Publication number
- WO2011057267A1 WO2011057267A1 PCT/US2010/056031 US2010056031W WO2011057267A1 WO 2011057267 A1 WO2011057267 A1 WO 2011057267A1 US 2010056031 W US2010056031 W US 2010056031W WO 2011057267 A1 WO2011057267 A1 WO 2011057267A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- influenza
- alum
- composition
- protein
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 64
- 229960005486 vaccine Drugs 0.000 title description 22
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 116
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 111
- 230000001717 pathogenic effect Effects 0.000 claims abstract description 63
- 244000052769 pathogen Species 0.000 claims abstract description 29
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims abstract description 23
- 239000000556 agonist Substances 0.000 claims abstract description 20
- 229940037003 alum Drugs 0.000 claims description 84
- 102000011931 Nucleoproteins Human genes 0.000 claims description 65
- 108010061100 Nucleoproteins Proteins 0.000 claims description 65
- 229940035032 monophosphoryl lipid a Drugs 0.000 claims description 61
- 238000000034 method Methods 0.000 claims description 47
- 208000015181 infectious disease Diseases 0.000 claims description 37
- 201000010099 disease Diseases 0.000 claims description 35
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 35
- 206010022000 influenza Diseases 0.000 claims description 30
- 208000037797 influenza A Diseases 0.000 claims description 23
- 238000007912 intraperitoneal administration Methods 0.000 claims description 17
- 241000700605 Viruses Species 0.000 claims description 16
- 102000002689 Toll-like receptor Human genes 0.000 claims description 15
- 108020000411 Toll-like receptor Proteins 0.000 claims description 15
- 239000002158 endotoxin Substances 0.000 claims description 14
- 229920006008 lipopolysaccharide Polymers 0.000 claims description 14
- 101100481579 Mus musculus Tlr11 gene Proteins 0.000 claims description 10
- 101100481580 Mus musculus Tlr12 gene Proteins 0.000 claims description 10
- 239000000443 aerosol Substances 0.000 claims description 8
- 241000282414 Homo sapiens Species 0.000 claims description 7
- 238000007920 subcutaneous administration Methods 0.000 claims description 6
- 101000763579 Homo sapiens Toll-like receptor 1 Proteins 0.000 claims description 5
- 101000763537 Homo sapiens Toll-like receptor 10 Proteins 0.000 claims description 5
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 claims description 5
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 claims description 5
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims description 5
- 101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 claims description 5
- 101000669406 Homo sapiens Toll-like receptor 6 Proteins 0.000 claims description 5
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 claims description 5
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 claims description 5
- 101100481581 Mus musculus Tlr13 gene Proteins 0.000 claims description 5
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 claims description 5
- 229940123384 Toll-like receptor (TLR) agonist Drugs 0.000 claims description 5
- 102100027010 Toll-like receptor 1 Human genes 0.000 claims description 5
- 102100027009 Toll-like receptor 10 Human genes 0.000 claims description 5
- 102100024333 Toll-like receptor 2 Human genes 0.000 claims description 5
- 102100024324 Toll-like receptor 3 Human genes 0.000 claims description 5
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims description 5
- 102100039357 Toll-like receptor 5 Human genes 0.000 claims description 5
- 102100039387 Toll-like receptor 6 Human genes 0.000 claims description 5
- 102100039390 Toll-like receptor 7 Human genes 0.000 claims description 5
- 102100033110 Toll-like receptor 8 Human genes 0.000 claims description 5
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 5
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims description 5
- 238000007918 intramuscular administration Methods 0.000 claims description 5
- DAZSWUUAFHBCGE-KRWDZBQOSA-N n-[(2s)-3-methyl-1-oxo-1-pyrrolidin-1-ylbutan-2-yl]-3-phenylpropanamide Chemical compound N([C@@H](C(C)C)C(=O)N1CCCC1)C(=O)CCC1=CC=CC=C1 DAZSWUUAFHBCGE-KRWDZBQOSA-N 0.000 claims description 5
- 244000045947 parasite Species 0.000 claims description 5
- 229940050271 potassium alum Drugs 0.000 claims description 5
- GNHOJBNSNUXZQA-UHFFFAOYSA-J potassium aluminium sulfate dodecahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.[Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GNHOJBNSNUXZQA-UHFFFAOYSA-J 0.000 claims description 5
- 241000894006 Bacteria Species 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 4
- 201000004792 malaria Diseases 0.000 claims description 4
- 210000002345 respiratory system Anatomy 0.000 claims description 4
- 241000701161 unidentified adenovirus Species 0.000 claims description 4
- 241000709661 Enterovirus Species 0.000 claims description 3
- 101710199771 Matrix protein 1 Proteins 0.000 claims description 3
- 101710199769 Matrix protein 2 Proteins 0.000 claims description 3
- 230000002378 acidificating effect Effects 0.000 claims description 3
- 208000037798 influenza B Diseases 0.000 claims description 3
- 208000037799 influenza C Diseases 0.000 claims description 3
- 101100028758 Influenza A virus (strain A/Swine/Wisconsin/1/1967 H1N1) PB1-F2 gene Proteins 0.000 claims description 2
- 206010024641 Listeriosis Diseases 0.000 claims description 2
- 101150103639 PB1 gene Proteins 0.000 claims description 2
- 102100033117 Toll-like receptor 9 Human genes 0.000 claims 2
- 230000004224 protection Effects 0.000 abstract description 22
- 210000004027 cell Anatomy 0.000 description 150
- 241000699670 Mus sp. Species 0.000 description 106
- 210000001744 T-lymphocyte Anatomy 0.000 description 89
- 239000000427 antigen Substances 0.000 description 49
- 108091007433 antigens Proteins 0.000 description 49
- 102000036639 antigens Human genes 0.000 description 49
- 150000007523 nucleic acids Chemical class 0.000 description 44
- 108010058846 Ovalbumin Proteins 0.000 description 37
- 108020004707 nucleic acids Proteins 0.000 description 36
- 102000039446 nucleic acids Human genes 0.000 description 36
- 229940092253 ovalbumin Drugs 0.000 description 35
- 108090000765 processed proteins & peptides Proteins 0.000 description 35
- JVJGCCBAOOWGEO-RUTPOYCXSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-4-amino-2-[[(2s,3s)-2-[[(2s,3s)-2-[[(2s)-2-azaniumyl-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxylatobutanoyl]amino]-6-azaniumy Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=CC=C1 JVJGCCBAOOWGEO-RUTPOYCXSA-N 0.000 description 34
- 238000002474 experimental method Methods 0.000 description 28
- 230000003053 immunization Effects 0.000 description 25
- 238000002649 immunization Methods 0.000 description 25
- 239000002671 adjuvant Substances 0.000 description 24
- 230000014509 gene expression Effects 0.000 description 21
- 230000004044 response Effects 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 17
- VDABVNMGKGUPEY-UHFFFAOYSA-N 6-carboxyfluorescein succinimidyl ester Chemical compound C=1C(O)=CC=C2C=1OC1=CC(O)=CC=C1C2(C1=C2)OC(=O)C1=CC=C2C(=O)ON1C(=O)CCC1=O VDABVNMGKGUPEY-UHFFFAOYSA-N 0.000 description 16
- 230000003612 virological effect Effects 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 14
- 230000001472 cytotoxic effect Effects 0.000 description 13
- 230000028993 immune response Effects 0.000 description 13
- 102000004889 Interleukin-6 Human genes 0.000 description 12
- 108090001005 Interleukin-6 Proteins 0.000 description 12
- 231100000433 cytotoxic Toxicity 0.000 description 12
- 210000000952 spleen Anatomy 0.000 description 12
- 102000001398 Granzyme Human genes 0.000 description 11
- 108060005986 Granzyme Proteins 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 11
- 238000011813 knockout mouse model Methods 0.000 description 11
- 210000004072 lung Anatomy 0.000 description 11
- 238000012986 modification Methods 0.000 description 11
- 230000004069 differentiation Effects 0.000 description 10
- 230000004048 modification Effects 0.000 description 10
- 230000001681 protective effect Effects 0.000 description 10
- 238000010186 staining Methods 0.000 description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 210000004988 splenocyte Anatomy 0.000 description 9
- 101000693922 Bos taurus Albumin Proteins 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 230000007402 cytotoxic response Effects 0.000 description 7
- 108020001507 fusion proteins Proteins 0.000 description 7
- 102000037865 fusion proteins Human genes 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- 102000043131 MHC class II family Human genes 0.000 description 6
- 108091054438 MHC class II family Proteins 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 230000002163 immunogen Effects 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- -1 lipidic derivatives Proteins 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000014102 antigen processing and presentation of exogenous peptide antigen via MHC class I Effects 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 230000002147 killing effect Effects 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 210000004989 spleen cell Anatomy 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 230000004580 weight loss Effects 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 102000004503 Perforin Human genes 0.000 description 4
- 108010056995 Perforin Proteins 0.000 description 4
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000006978 adaptation Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 210000000349 chromosome Anatomy 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000028996 humoral immune response Effects 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000005015 mediastinal lymph node Anatomy 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 229930192851 perforin Natural products 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000001603 reducing effect Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241000712461 unidentified influenza virus Species 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 3
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 3
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 description 3
- 108090000978 Interleukin-4 Proteins 0.000 description 3
- 102000004388 Interleukin-4 Human genes 0.000 description 3
- 102000018697 Membrane Proteins Human genes 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- 230000005867 T cell response Effects 0.000 description 3
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002519 immonomodulatory effect Effects 0.000 description 3
- 239000000367 immunologic factor Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000021633 leukocyte mediated immunity Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000003068 molecular probe Substances 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000037452 priming Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 229940031626 subunit vaccine Drugs 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 241000272517 Anseriformes Species 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 101150014003 Batf3 gene Proteins 0.000 description 2
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 2
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 108091054437 MHC class I family Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 230000003092 anti-cytokine Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 210000000172 cytosol Anatomy 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 230000009675 homeostatic proliferation Effects 0.000 description 2
- 230000004727 humoral immunity Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 229960003971 influenza vaccine Drugs 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000010212 intracellular staining Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000003071 memory t lymphocyte Anatomy 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 201000009240 nasopharyngitis Diseases 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010011416 Croup infectious Diseases 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000272496 Galliformes Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 101150081923 IL4 gene Proteins 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 108010015268 Integration Host Factors Proteins 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 1
- MQUQNUAYKLCRME-INIZCTEOSA-N N-tosyl-L-phenylalanyl chloromethyl ketone Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N[C@H](C(=O)CCl)CC1=CC=CC=C1 MQUQNUAYKLCRME-INIZCTEOSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 1
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 230000037453 T cell priming Effects 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 108010004469 allophycocyanin Proteins 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 210000004970 cd4 cell Anatomy 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 229940106135 cellulose Drugs 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 201000010549 croup Diseases 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 231100000050 cytotoxic potential Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 229930004094 glycosylphosphatidylinositol Natural products 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000007498 myristoylation Effects 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000000863 peptide conjugate Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000013823 prenylation Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical class CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 210000005212 secondary lymphoid organ Anatomy 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003970 toll like receptor agonist Substances 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 210000003956 transport vesicle Anatomy 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/235—Adenoviridae
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the field of the present invention generally relates to the production and use of vaccines against pathogens.
- Immunotherapeutic compositions including vaccines, are one of the most cost- effective measures available to the health care industry for the prevention and treatment of disease. There remains, however, an urgent need to develop safe and effective
- immunotherapy strategies and adjuvants for a variety of diseases, including those caused by or associated with infection by pathogens.
- infectious diseases including viral diseases and diseases caused by intracellular pathogens
- Pathogen specific CD8 T cells can provide protective responses in both animal models and in humans by, for example, killing infected cells (Harty, J.T., et al. 2000. Annu Rev Immunol 18:275-308). However, most current vaccines act by generating specific antibodies that either neutralize or otherwise inactivate the pathogen (Plotkin, S.A. 2008. Clin Infect Dis 47:401-409).
- the influenza vaccine acts in this way: antibodies to the surface protein, haemagglutinin (HA), bind and inactivate the virus before it can infect host cells, thereby providing sterilizing immunity; the most optimal form of immune protection.
- HA and the other major antibody target, neuramindase (NA), alter year by year as a result of mutation and reassortment of viral genes leading to viral escape from immunodetection (Webster, R.G., et al. 1992. Microbiol Rev 56:152-179).
- CD8 T cell influenza epitopes are more likely to be found in the less variable internal core proteins of the virus and influenza specific cells have been found to recognize different viral sub-types (Boon, A.C., et al. 2004. J Immunol 172:2453-2460; Braciale, T.J. 1977. J Exp Med 146:673-689; Jameson, J., et al.1999. J Immunol
- influenza specific T cells can provide cross-reactive protection in mice and their presence is associated with reduced viral levels and disease in humans (Christensen, J.P., et al. 2000. J Virol 74: 11690-11696; Epstein, S.L. 2006. J Infect Dis 193:49-53; Furuya, Y., et al. 2010.
- CD8 T cells can only act to reduce disease following an infection as their activation requires processing and presentation of antigen on MHC class I molecules. Despite this, there has been growing interest in the development of vaccines that generate protective CD 8 T cells as many diseases cannot be effectively controlled by antibody alone (Appay, V., et al. 2008. Nat Med 14:623-628; Doherty, P.C., and Kelso, A. 2008. J Clin Invest 118:3273-3275).
- Vaccines fall into two main categories: those that contain the whole
- sub-unit vaccines which has either been attenuated or inactivated, and those that are made up of parts of the pathogen, these are known as sub-unit vaccines. While vaccines in the former category contain both antigen and innate-stimulating components that provide all the signals required to activate fully the adaptive immune response, sub-unit vaccines must be given with an adjuvant to provide an effective stimulatory environment (McKee, A.S. et al. 2010. BMC Biol 8:37).
- Antigen specific CD8 T cells are activated following immunization of mice with protein and the aluminum salt, alyhdrogel (also referred to as alum) (McKee, A.S., et al. 2009. J Immunol 183:4403-4414).
- Alum causes destabilizaton of endocytic vesicles allowing co-injected antigens to enter the cytosol (Hornung, V., et al. 2008. Nat Immunol 9:847-856). This should allow all APC that phagocytose antigen delivered with alum to have the potential to present to CD8 T cells. That this is not the case suggests that simply the presence of antigen in the cytosol is not sufficient for the activation of CD 8 T cells.
- the present invention provides for a composition comprising an isolated internal pathogenic protein, a Toll-like receptor (TLR) agonist and an aluminum salt.
- the isolated internal pathogenic protein can be selected from the group consisting of influenza nucleoprotein (NP), matrix protein 1 (Ml), matrix protein 2 (M2), non-structural- 1 (NS1), non-structrual-2 (NS2), polymerase acidic (PA), polymerase basic 1 (PB1), polymerase basic 1 F2 (PB2-F2), and polymerase basic 2 (PB2), and in a preferred embodiment, the isolated internal pathogenic protein is NP and further, the NP can be from influenza A.
- composition of the present invention provides that the isolated internal pathogenic protein is from a pathogen that can be selected from the group consisting of a virus, parasite and bacteria.
- composition of the present invention further provides that the
- TLR agonist is selected from the group consisting of TLR1, TLR2, TLR3, TLR4, TLR5,
- the TLR agonist is selected from the group consisting of a lipopolysaccharide (LPS) derivative or mimetic, monophosphoryl lipid A (MPL) or RC529.
- LPS lipopolysaccharide
- MPL monophosphoryl lipid A
- RC529 monophosphoryl lipid A
- the LPS derivative is MPL.
- the aluminum salt is selected from the group consisting of alum, potassium aluminum sulfate, aluminum phosphate, and aluminum hydroxide. In a preferred aspect of the composition of the present invention the aluminum salt is alum.
- the composition may be administered to a subject orally, subcutaneous ly, intramuscularly, intravenously, by aerosol to the respiratory tract, or intradermally.
- composition of the present invention comprising an influenza A nucleoprotein, MPL and alum.
- the present invention also provides for a method for protecting a subject against infection by a pathogen comprising administering to the subject a composition comprising an isolated internal pathogenic protein, a Toll-like receptor (TLR) agonist and an aluminum salt.
- TLR Toll-like receptor
- the pathogen can be capable of causing a disease selected from the group consisting of influenza, a rhinovirus associated disease, adenovirus associated disease, malaria and Listeria infection.
- influenza can be selected from the group consisting of influenza A, influenza B and influenza C.
- this method provides that the isolated internal pathogenic protein is selected from the group consisting of influenza nucleoprotein (NP), Ml, M2, NS1, NS2, PA, PBl, PB1-F2, PB2.
- the method further provides that the isolated internal pathogenic protein can be NP.
- the NP is from influenza A.
- the TLR agonist is selected from the group consisting of TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, TLR11, TLR12, and TLR13.
- the TLR agonist is selected from the group consisting of a lipopolysaccharide (LPS) derivative or mimetic, MPL or RC529. In a preferred embodiment the method provides that the LPS derivative is MPL.
- LPS lipopolysaccharide
- the aluminum salt is selected from the group consisting of alum, potassium aluminum sulfate, aluminum phosphate, and aluminum hydroxide.
- the aluminum salt is alum.
- the route of administration may be intra-peritoneal (i.p.), oral, subcutaneous, intramuscular, intravenous, by aerosol to the respiratory tract, or intradermal.
- the present invention also provides a method for protecting a subject against infection by influenza comprising administering to the subject a composition comprising an influenza A nucleoprotein, MPL and alum.
- the subject is human.
- Figures 1A-1C show that protein delivered with alum primes antigen specific memory CD 8 T cells.
- FIG 1 A B6 mice were immunized with OVA + alum or were not immunized and the percent of Kb/SIINFEKL (SEQ ID NO: l) tetramer+ cells in the spleen was examined 9 days later. Cells are gated on live CD8+ lymphocytes that were negative for B220, CD4, F4/80 and MHC class II. The numbers are the percent of cells within the indicated gate.
- the data shown are representative of 8 experiments with 3-4 mice/group. In figure IB the experiments were performed as in figure 1A, but the phenotype of the Kb/SIINFEKL (SEQ ID NO: l) tetramer+ cells 60 days after
- Kb/SIINFEKL (SEQ ID NO: l) tetramer+ gates (light grey line) or CD8+ cells (closed grey histrogram with dark line).
- the data are representative of 3-4 experiments with 3-4 mice/group.
- the experiments were performed as in figure 1A, but the numbers of Kb/SIINFEKL (SEQ ID NO: l) tetramer+ cells were examined at various times after immunization, cells were gated as in figure 1 A.
- the horizontal line indicates the level of detection as determined by staining spleen cells from naive age-matched mice.
- the data are from two experiments with a total of 8 mice per time point.
- FIGs 2A-2D show that CD8, but not CD4, T cell responses are reduced in the absence of Batf3.
- BatO heterozygous (HET) and deficient (KO) mice were primed with 3K-OVA + alum intraperitoneal (i.p.) and the percent of CD4 T cells that bound to IAb/3K tetramer examined 8 days later.
- Cells were gated on live CD4+ lymphocytes negative for B220, CD8, F4/80 and MHC class II. The number shows the percent of IAb/3K tetramer+ CD44hi cells in the adjacent gates.
- FIG 2B the number of IAb/3K tetramer+ CD44hi cells in the mice in figure 2A and similarly treated wild-type B6 (WT) mice was calculated. Each symbol represents a mouse and the line shows the mean of the group. The data are representative of 3 experiments with 3 mice per group.
- FIG 2C the percent of CD8 T cells that bound to the Kb/SIINFEKL (SEQ ID NO: l) tetramer was examined on mice treated as in figure 2A. The number shows the percent of Kb/SIINFEKL (SEQ ID NO: l) + CD44hi cells in the adjacent box. Cells are gated on live CD8+ lymphocytes negative for B220, CD4, F4/80 and MHC class II.
- FIGs 3A and 3B show that alum activated CD8 T cells make IFNy not IL4.
- the percents of IAb/3K tetramer or Kb/SIINFEKL (SEQ ID NO: 1) tetramer+ cells in the spleen were measured and the percent of these cells that were GFP+ cells determined (indicated as "recall" on the figure).
- Cells were gated either on CD4+ live lymphocytes that were B220, CD8, F4/80 and MHC II negative (row 1) and on the IAb/3K tetramer CD44hi cells (row 2). In row 3 the cells were gated as in figure 1 A and on Kb/SIINFEKL (SEQ ID NO: l) tetramer+ CD44hi cells in row 4.
- Numbers shown are the percent of cells within the indicated gate or quadrant.
- the data shown are representative of 1-2 experiments with 4 mice/group.
- FIG 3B eight days after B6 mice were primed with OVA + alum their splenocytes were activated with SIINFEKL (SEQ ID NO: 1) peptide for 6 hours in the presence of Golgi plug or with Golgi plug alone.
- the cells in the plots are gated on CD8+ B220-CD4-MHC class Il-cells.
- the number indicates the percent of cells in the indicated gate that were CD44hi IFNy+.
- the data shown are representative of 8 experiments with 3-4 mice per group.
- Figures 4A-4D show that mice primed with a CD8 epitope from influenza nucleoprotein, alum and MPL are protected from influenza A infection.
- B6 mice were immunized with BSA/NP + alum or were not immunized and the percent of Db/NP tetramer+ cells in the spleen was examined 9 days later. Cells were gated as in figure 1 A. The numbers indicate the percent of cells in the adjacent gate. Plots are representative of 2 experiments with 3-4 mice/group.
- mice were immunized with NP/OVA or NP/BSA either alone (closed diamonds) or with alum (open diamonds), MPL (open squares) or both alum and MPL (closed squares) or with the two adjuvants and PBS (closed triangles). 5-14 weeks later, the mice were infected with 150 plaque forming units (PFU) of influenza A intranasally (i.n.) and weighed every day. The data shown are combined from 2 experiments with 4-5 mice/group. In figure 4C the experiments were performed as in figure 4B, but the numbers of Db/NP tetramer+ cells, in one lobe of the lung, were examined on day 4 by flow cytometry.
- PFU plaque forming units
- Figure 5 shows that protected and control mice have similar numbers of antigen specific cells in the MLN and lung 8 days after infection.
- the experiments were performed as in figure 4 but MLN (A and C) or lungs (B and D) were taken 8 days after infection with
- Figures 6A-6E show the addition of MPL does not affect T cell priming but enhances cytotoxic differentiation.
- FIG 6A B6 mice were immunized with OVA + alum, MPL or both adjuvants and the numbers of Kb/SIINFEKL (SEQ ID NO: l) tetramer+ cells in spleens examined. Cells were gated as in figure 1 A. The horizontal line indicates the level of detection. The data shown are representative of 2 experiments with 4 mice/group.
- figure 6B B6 mice were primed with NP/OVA or NP/BSA with the indicated adjuvant and the numbers of Db/NP tetramer+ cells in spleens examined 6-14 weeks later.
- Each symbol represents a mouse and the line shows the group mean.
- the horizontal line indicates the level of detection.
- the data are from 3 experiments with 3-4 mice/group.
- FIG 6C B6 mice were primed with OVA and alum, MPL or both adjuvants i.p. 7 days later these mice and na ' ive mice received a 1 : 1 mixture of splenocytes half of which had been incubated with SIINFEKL (SEQ ID NO: 1) peptide and stained with a high level of CFSE and the second half stained with a low level of CFSE. Two days later, the percent of total CFSE positive cells that were CFSEhi was examined in the spleen. A representative sample from each group is shown.
- mice The number indicates the percent of CFSEhi cells out of total CFSE+ cells.
- B6 and IL6 knockout mice were immunized with OVA delivered with alum or alum + MPL i.p. and 7 days later these mice received SIINFEKL (SEQ ID NO: l) -loaded, CFSE stained cells as in figure 6C and the percent of CFSEhi peptide loaded cells out of total CFSE+ cells in the spleen examined 2 days later. Each symbol represents one mouse and the line shows the mean of the group, n.s.: not significant.
- figure 6E B6 and perforin knockout mice were primed with NP/OVA with alum + MPL or B6 mice were given adjuvant alone. 6 weeks later, these mice were infected with 150 PFU of influenza A i.n and the mice weighed daily. The data are representative of 1 of 2 experiments with 5 mice/group.
- Figures 7A-7E shows PD 1 upregulation on alum primed cells inhibits cytotoxic differentiation.
- B6 mice were primed with OVA and alum, MPL or both adjuvants i.p. and the levels of PDl expression on the surface of Kb/SIINFEKL (SEQ ID NO: l) tetramer positive cells examined 8 days later.
- Cells are gated on Kb/SIINFEKL (SEQ ID NO: l) + CD44hi cells (open histograms) or on total CD8 T cells from a naive animal (filled histogram).
- Figure 8 shows that MPL does not alter the number of IFN ⁇ produced after immunization with OVA and alum.
- SIINFEKL SEQ ID NO: 1
- the numbers of CD8+CD4-MHCII-B220- that were IFN ⁇ + were examined by intracellular staining. Each symbol represents one mouse and the line shows the mean of the group.
- the horizontal line indicates the level of background staining of spleen cells cultured with Golgi Plug in the absence of peptide.
- the data are representative of 3 experiments with 4 mice per group in each experiment.
- FIG. 9 shows that MPL enhances the cytotoxic response of alum-primed CD8 T cells.
- B6 mice were primed with OVA and alum, MPL or both adjuvants i.p. 7 days later these mice and naive mice received a 1 : 1 mixture of splenocytes half of which had been incubated with SIINFEKL (SEQ ID NO: l) peptide and stained with a high level of CFSE and the second half stained with a low level of CFSE.
- SIINFEKL SEQ ID NO: l
- Figure 10 shows that anti-PDLl treatment does not affect the number of IFN ⁇ producing cells activated after immunization with alum and antigen B6 mice were primed with OVA and alum i.p. on day 0 and treated with anti-PDLl or an isotype control antibody on days 0, 3 and 7.
- spleen cells were activated with SIINFEKL (SEQ ID NO: 1) peptide in the presence of Golgi plug and the number of IFNy+ CD8+ cells calculated.
- SIINFEKL SEQ ID NO: 1
- Each symbol represents a mouse and the line shows the mean of the group. Data is representative of two experiments with 4 mice per group.
- the horizontal line indicates the level of background staining of spleen cells incubated with Golgi plug in the absence of peptide.
- the present invention generally relates to compositions and methods for protection against infection by a pathogen.
- the invention includes a composition comprising an isolated internal pathogenic protein, a toll-like receptor agonist and an aluminum salt, as well as the use of such compositions for protecting a subject against infection by a pathogen.
- CD8 T cells can provide protective responses in both animal models and in humans.
- CD8 T cell epitopes are much less variable and thus a vaccine designed to activate protective CD8 T cells has the potential to protect against yearly and newly emerging pandemic viral subtypes.
- the CD8 T cells in both mouse and man cross-react across different sub-types of influenza virus. Therefore, a vaccine that generates CD8 T cells may provide cross-reactive protection in influenza.
- one of the major risk groups for influenza infection are the elderly who make poor B cell responses to new vaccines. By generating CD8 memory T cells, these individuals may be more likely to be protected.
- the presence of granzyme expressing influenza specific CD8 T cells provides a better correlate of protection from influenza in elderly individuals than the presence of HA specific antibodies.
- the internal pathogenic protein influenza nucleoprotein is highly conserved between different strains of the influenza A viruses and human CD8 T cells reactive to a number of epitopes within nucleoprotein respond to a range of viruses including H5N1 virus subtypes.
- the cross reactivity of NP specific CD8 T cells for different strains of influenza A has been recognized and such cells have been shown to provide protection from heterosubtypic influenza challenge by a number of groups.
- a vaccine composition of the present invention has clear advantages over other current vaccines because many of these vaccines induce protective antibodies to viral surface proteins but do not offer protections against annual variants or emerging pathogenic strains.
- the present invention demonstrates that a composition comprising an isolated internal pathogenic protein, and aluminum salt and a TLR agonist results in a protective response to infection in vivo. Without being bound by theory, the generation of memory
- CD 8 T cells is activated with antigen delivered with aluminum salt.
- the resultant memory cells are long-lived and can protect animals from disease following infection with the pathogen from which the pathogenic protein is derived.
- the addition of MPL enhances protection by increasing the differentiation of the activated
- T cells into cytotoxic cells CTLs
- CTLs cytotoxic cells
- IL interleukin 6
- PD1 programmed death 1 receptor
- the increased PD1 expression on T cell primed in the presence of alum reduced the cytotoxic response as blocking interactions between PD1 and PDL1 (programmed death ligand) increase granzyme B expression and improve the cytotoxic response of the CD8 T cells.
- a entity or “an” entity refers to one or more of thai entity.
- a host factor refers to one or more host factors.
- the terms “a”, “an”, “one or more” and “at least one” can be used interchangeably.
- the terms “comprising”, “including” and “having” can be used interchangeably.
- compositions of the present invention are a composition comprising an isolated internal pathogenic protein, a TLR agonist and an aluminum salt.
- isolated pathogenic protein refers to any non-surface proteins of a pathogen and includes whole proteins, internal portions of transmembrane proteins, peptides, and protein fragments.
- Compositions of the present invention in some embodiments can include two or more isolated internal pathogenic proteins.
- the isolated internal pathogenic protein encompassed by the invention can include at least a portion or the full-length of any one or more influenza proteins selected from nucleoprotein (NP), matrix protein 1 (Ml), matrix protein 2 (M2), non- structural- 1 (NSl), non-structrual-2 (NS2), polymerase acidic (PA), polymerase basic
- the isolated internal pathogenic protein is the influenza A NP protein.
- Isolated internal pathogenic proteins of the present invention can be derived from any suitable pathogen.
- the pathogen can be a virus, parasite or bacteria.
- the internal pathogenic protein is derived from rhinovirus.
- the isolated internal pathogenic protein is derived from adenovirus.
- the isolated internal pathogenic protein is derived from a parasite (such as the parasite that causes malaria).
- the isolated internal pathogenic protein is derived from a bacteria (such as Listeria).
- the isolated internal pathogenic protein can function as an antigen.
- the general use herein of the term "antigen” refers: to any portion of a protein (peptide, partial protein, full-length protein), wherein the protein is naturally occurring or synthetically derived, to a cellular composition (whole cell, cell lysate or disrupted cells), to an organism (whole organism, lysate or disrupted cells) or to a carbohydrate, or other molecule, or a portion thereof.
- An antigen may elicit an antigen-specific immune response (e.g., a humoral and/or a cell-mediated immune response) against the same or similar antigens that are encountered by an element of the immune system ⁇ e.g., T cells, antibodies).
- an antigen-specific immune response e.g., a humoral and/or a cell-mediated immune response
- an element of the immune system e.g., T cells, antibodies
- An antigen can be as small as a single epitope, or larger, and can include multiple epitopes.
- the size of an antigen can be as small as about 5-12 amino acids ⁇ e.g., a peptide) and as large as: a full length protein, including a multimer and fusion proteins, chimeric proteins, whole cells, whole microorganisms, or portions thereof (e.g., lysates of whole cells or extracts of microorganisms).
- antigens can include
- the antigen is a protein, fusion protein, chimeric protein, or fragment thereof, rather than an entire cell or microorganism.
- an "immunogenic domain" of a given antigen can be any portion, fragment or epitope of an antigen ⁇ e.g., a peptide fragment or subunit or an antibody epitope or other conformational epitope) that contains at least one epitope that acts as an immunogen when administered to an animal.
- a single protein can contain multiple different immunogenic domains. Immunogenic domains need not be linear sequences within a protein, such as in the case of a humoral immune response.
- An epitope is defined herein as a single immunogenic site within a given antigen that is sufficient to elicit an immune response.
- T cell epitopes are different in size and composition from B cell epitopes, and that epitopes presented through the Class I MHC pathway differ from epitopes presented through the Class II MHC pathway.
- Epitopes can be linear sequence or conformational epitopes (conserved binding regions).
- the invention also includes homologues of any of the above-described internal pathogenic proteins, as well as the use of homologues, variants, or mutants of the individual internal pathogenic proteins or portions thereof.
- the TLR agonist may be a TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, TLR11, TLR12, or TLR13 agonist.
- TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, TLR11, TLR12, or TLR13 agonist examples include, without limitation, a
- LPS lipopolysaccharide
- the aluminum salt is alum, potassium aluminum sulfate, aluminum phosphate, or aluminum hydroxide. In a preferred embodiment the aluminum salt is alum.
- a composition comprising an isolated internal pathogenic protein adjuvanted with alum, protects mice from some of the weight loss associated with influenza infection.
- Addition of the TLR agonist, MPL to the formulation did not alter the number of CD8 memory cells generated with alum alone but improved protection by increasing the differentiation of cytotoxic cells. This protection was observed by a reduction in both weight loss and viral titers following infection. While antigen (isolated internal pathogenic protein) and MPL alone activated a good primary response including substantial cytotoxic T cell differentiation, these cells were unable to protect mice from subsequent influenza infection. This was due to the poor survival of the memory cells generated by this immunization. Therefore, alum and MPL complement each other: alum provides signals required for the generation of long-lived memory cells while MPL enhances cytotoxic differentiation.
- IL6 may be produced in the spleen and act either on the priming APC or directly on the activated CD8 T cells.
- IL6 can enhance the differentiation of cytotoxic CD8 T cells in the presence of IL2 in vitro following activation of purified CD8 T cells with anti- CD3 and anti-CD28 (32).
- MPL also reduces the expression of PD1 on the alum-primed CD 8 T cells and that this contributes to its ability to enhance the CD8 T cell cytotoxic response.
- the high expression of PD1 by the alum-primed CD8 T cells led to a reduction in granzyme B expression, and therefore the majority of these cells did not differentiate into cytotoxic cells. Consequently, when the memory cells generated from this response were re-activated by the influenza A infection, they first had to differentiate into cytotoxic cells before they could provide protection, potentially explaining why these cells provided less protection than those primed with both alum and MPL.
- CD8 T cells can only recognize a virus following active infection of host cells, the immunization did not prevent infection following challenge. As a result of this, a primary immune response to other epitopes of the virus occurred. For example, the numbers of CD8 T cells responding to the PA224-233 epitope were similar in immunized and control animals. Infection in the absence of severe disease may actually provide long- term advantages. A low level of infection, as seen here in mice immunized with
- NP/protein and both an aluminum salt and TLR will allow the immune system to be primed or boosted to the virus, enhancing future protection whilst preventing disease.
- a composition can include additional agents, which may also be referred to as biological response modifier compounds, or the ability to produce such agents/modifiers.
- Biological response modifiers include additional adjuvants and other compounds that can modulate immune responses, which may be referred to as immunomodulatory compounds, as well as compounds that modify the biological activity of another compound or agent, such biological activity not being limited to immune system effects.
- immunomodulatory compounds can stimulate a protective immune response whereas others can suppress a harmful immune response, and whether an immunomodulatory is useful in combination with the composition may depend, at least in part, on the disease state or condition to be prevented, and/or on the individual who is to be treated.
- Certain biological response modifiers preferentially enhance a cell-mediated immune response whereas others preferentially enhance a humoral immune response (i.e., can stimulate an immune response in which there is an increased level of cell-mediated compared to humoral immunity, or vice versa.).
- a humoral immune response i.e., can stimulate an immune response in which there is an increased level of cell-mediated compared to humoral immunity, or vice versa.
- Agents/biological response modifiers useful in the invention may include, but are not limited to, cytokines, chemokines, hormones, lipidic derivatives, peptides, proteins, polysaccharides, small molecule drugs, antibodies and antigen binding fragments thereof (including, but not limited to, anti-cytokine antibodies, anti-cytokine receptor antibodies, anti-chemokine antibodies), vitamins, polynucleotides, nucleic acid binding moieties, aptamers, and growth modulators.
- Agents can include agonists and antagonists of a given protein or peptide or domain thereof.
- an "agonist” is any compound or agent, including without limitation small molecules, proteins, peptides, antibodies, nucleic acid binding agents, etc., that binds to a receptor or ligand and produces or triggers a response, which may include agents that mimic the action of a naturally occurring substance that binds to the receptor or ligand.
- An "antagonist” is any compound or agent, including without limitation small molecules, proteins, peptides, antibodies, nucleic acid binding agents, etc., that blocks or inhibits or reduces the action of an agonist.
- the present invention includes a method for protecting a subject against infection by a pathogen comprising administering to the subject a composition comprising an isolated internal pathogenic protein, a TLR and an aluminum salt.
- the pathogen is capable of causing a disease including but not limited to, influenza (influenza A, B and C), rihinovirusal related diseases (the common cold), adenovirus related diseases (respiratory diseases such as common cold, pneumonia, croup, and bronchitis as well as infection of the stomach and intestine (gastroenteritis), eyes (conjunctivitis), and bladder (cystitis)) and malaria.
- the composition may be administered to induce a CD8+ immune response in the subject.
- viral disease e.g., a viral-associated disease
- parasitic disease e.g., a viral-associated disease
- the composition may be administered to induce a CD8+ immune response in the subject.
- Another embodiment of the invention relates to a method to immunize an individual or population of individuals against a pathogen in order to prevent pathogenic infection, and/or reduce the severity of pathogenic infection in the individual or population of individuals.
- the method includes the step of administering to an individual or population of individuals that is not infected with the pathogen (or believed not to be infected with the pathogen), a composition of the invention.
- composition of one embodiment of the invention may be administered using techniques well known to those in the art.
- compounds are formulated and administered by genetic immunization.
- Techniques for formulation and administration may be found in "Remington's Pharmaceutical Sciences", 18 th ed., 1990, Mack Publishing Co., Easton, PA.
- Suitable routes may include parenteral delivery, such as intramuscular, intradermal, subcutaneous, intramedullary injections, as well as, intrathecal, direct intraventricular, intravenous, intraperitoneal, intranasal, or intraocular injections, just to name a few.
- Other routes include oral or transdermal deliver ⁇ '.
- the composition of one embodiment of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiological saline buffer.
- parenteral application which includes intramuscular, intradermal,
- subcutaneous, intranasal, mtracapsular, intraspinal, intrasteniaL and intravenous injection particularly suitable are injectable, sterile solutions, preferably oily or aqueous solutions, as well as suspensions, emulsions, or implants, including suppositories.
- Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative.
- the compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
- the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen- free water, before use.
- compositions may be prepared by conventional means with phannaceutically acceptable excipients such as binding agents (e.g., pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl)
- binding agents e.g., pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl
- methyleellulose methyleellulose
- fillers e.g., lactose, macrocrystalline cel lulose or calcium hydrogen phosphate
- lubricants e.g., magnesium stearate, talc or silica
- disintegrants e.g., potato starch or sodium starch glycolate
- wetting agents e.g., sodium lauryl sulphate
- the tablets may be coated by methods well known in the art.
- Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use.
- Such liquid preparations may be prepared by conventional means with phannaceutjcally acceptable additives such as suspending agents (e.g., sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (e.g., lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (e.g., methyl or propyl-p-hydroxybenzoates or sorbic acid).
- suspending agents e.g., sorbitol syrup, cellulose derivatives or hydrogenated edible fats
- emulsifying agents e.g., lecithin or acacia
- non-aqueous vehicles e.g., almond oil, oily esters, ethyl alcohol or fractionated vegetable oils
- preservatives e.g., methyl or propyl-p-hydroxybenzoates or sorbic acid
- Sustained or directed release compositions can be formulated, e.g., liposomes or those wherem the active compound is protected with differentially degradable coatings, e.g., by microencapsulation, multiple coatings, etc. It is also possible to freeze dry the new compounds and use the lyophilizates obtained, for example, for the preparation of products for injection.
- the compounds for use according to one embodiment of the present invention are con veniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propeliant, e.g., dichlorodifluoromethane, trichlorofluoromethane,
- the dosage unit may be determined by providing a valve to deliver a metered amount.
- Capsules and cartridges of e.g., gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.
- a suitable powder base such as lactose or starch.
- viscous to semi-solid or solid forms comprising a earner compatible with topical application and having a dynamic viscosity preferably greater than water.
- Suitable formulations include but are not limited to solutions, suspensions, emulsions, creams, ointments, powders, liniments, salves, aerosols, etc, which are, if desired, sterilized or mixed with auxiliary agents, e.g., preservatives, stabilizers, wetting agents, buffers or salts for influencing osmotic pressure, etc.
- auxiliary agents e.g., preservatives, stabilizers, wetting agents, buffers or salts for influencing osmotic pressure, etc.
- sprayable aerosol preparations wherein the active ingredient, preferably in combination with a solid or liquid inert carrier material, is packaged in a squeeze bottle or in admixture with a pressurized volatile, normally gaseous propellant, e.g. , a freon.
- compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient.
- the pack may for example comprise metal or plastic foil, such as a blister pack.
- the pack or dispenser device may be accompanied by instructions for administration.
- compositions may comprise a pharmaceutically acceptable excipieiit, carrier, buffer, stabilizer or other materials well known to those skilled in the art. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient.
- the precise nature of the carrier or other material may depend on the route of administration, e.g., intravenous, cutaneous or subcutaneous, intramucosal (e.g., gut), intranasal, intramuscular, or intraperitoneal routes.
- Subject refers to any member without limitation, humans and other primates, including non-human primates such as chimpanzees and other apes and monkey species; farm animals such as cattle, sheep, pigs, goats and horses; domestic mammals such as dogs and cats; laboratory animals including rodents such as mice, rats and guinea pigs; birds, including domestic, wild and game birds such as chickens, turkeys and other gallinaceous birds, ducks, geese, and the like.
- the term does not denote a particular age. Thus, both adult and newborn individuals are intended to be covered.
- the invention is intended for use involving any of the above vertebrate species, since the immune systems of all of these vertebrates operate similarly.
- biologically active indicates that a compound (including a protein or peptide) has at least one detectable activity that has an effect on the metabolic or other processes of a cell or organism, as measured or observed in vivo ⁇ i.e., in a natural physiological environment) or in vitro ⁇ i.e., under laboratory conditions).
- the term “modulate” can be used
- the term “upregulate” can be used generally to describe any of: elicitation, initiation, increasing, augmenting, boosting, improving, enhancing, amplifying, promoting, or providing, with respect to a particular activity.
- downregulate can be used generally to describe any of: decreasing, reducing, inhibiting, ameliorating, diminishing, lessening, blocking, or preventing, with respect to a particular activity.
- an isolated protein is a protein (including a polypeptide or peptide) that has been removed from its natural milieu (i.e., that has been subject to human manipulation) and can include purified proteins, partially purified proteins, recombinantly produced proteins, and synthetically produced proteins, for example.
- purified proteins does not reflect the extent to which the protein has been purified.
- an isolated protein of the present invention is produced recombinantly.
- the terms "modification” and “mutation” can be used interchangeably, particularly with regard to the modifications/mutations to the amino acid sequence of proteins or portions thereof (or nucleic acid sequences) described herein.
- homologue is used to refer to a protein or peptide which differs from a naturally occurring protein or peptide (i.e., the "prototype” or “wild-type” protein) by minor modifications to the naturally occurring protein or peptide, but which maintains the basic protein and side chain structure of the naturally occurring form.
- Such changes include, but are not limited to: changes in one or a few amino acid side chains; changes one or a few amino acids, including deletions (e.g., a truncated version of the protein or peptide) insertions and/or substitutions; changes in stereochemistry of one or a few atoms; and/or minor derivatizations, including but not limited to: methylation, glycosylation, phosphorylation, acetylation, myristoylation, prenylation, palmitation, amidation and/or addition of glycosylphosphatidyl inositol.
- a homologue can have either enhanced, decreased, or substantially similar properties as compared to the naturally occurring protein or peptide.
- a homologue can include an agonist of a protein or an antagonist of a protein.
- Homologues can be produced using techniques known in the art for the production of proteins including, but not limited to, direct modifications to the isolated, naturally occurring protein, direct protein synthesis, or modifications to the nucleic acid sequence encoding the protein using, for example, classic or recombinant DNA techniques to effect random or targeted mutagenesis.
- a homologue of a given protein may comprise, consist essentially of, or consist of, an amino acid sequence that is at least about 45%, or at least about 50%, or at least about 55%), or at least about 60%>, or at least about 65%, or at least about 70%>, or at least about 75%), or at least about 80%>, or at least about 85%, or at least about 90%>, or at least about 95% identical, or at least about 95% identical, or at least about 96% identical, or at least about 97% identical, or at least about 98% identical, or at least about 99% identical (or any percent identity between 45% and 99%, in whole integer increments), to the amino acid sequence of the reference protein.
- the homologue comprises, consists essentially of, or consists of, an amino acid sequence that is less than 100% identical, less than about 99% identical, less than about 98% identical, less than about 97% identical, less than about 96% identical, less than about 95% identical, and so on, in increments of 1%, to less than about 70% identical to the naturally occurring amino acid sequence of the reference protein.
- An isolated nucleic acid molecule is a nucleic acid molecule that has been removed from its natural milieu (i.e., that has been subject to human manipulation), its natural milieu being the genome or chromosome in which the nucleic acid molecule is found in nature.
- isolated does not necessarily reflect the extent to which the nucleic acid molecule has been purified, but indicates that the molecule does not include an entire genome or an entire chromosome in which the nucleic acid molecule is found in nature.
- An isolated nucleic acid molecule can include a gene.
- An isolated nucleic acid molecule that includes a gene is not a fragment of a chromosome that includes such gene, but rather includes the coding region and regulatory regions associated with the gene, but no additional genes that are naturally found on the same chromosome.
- An isolated nucleic acid molecule can also include a specified nucleic acid sequence flanked by (i.e., at the 5' and/or the 3' end of the sequence) additional nucleic acids that do not normally flank the specified nucleic acid sequence in nature (i.e., heterologous sequences).
- Isolated nucleic acid molecule can include DNA, RNA (e.g., mRNA), or derivatives of either DNA or RNA (e.g., cDNA).
- nucleic acid molecule primarily refers to the physical nucleic acid molecule and the phrase “nucleic acid sequence” primarily refers to the sequence of nucleotides on the nucleic acid molecule, the two phrases can be used interchangeably, especially with respect to a nucleic acid molecule, or a nucleic acid sequence, being capable of encoding a protein or domain of a protein.
- a recombinant nucleic acid molecule is a molecule that can include at least one of any nucleic acid sequence encoding any one or more proteins described herein operatively linked to at least one of any transcription control sequence capable of effectively regulating expression of the nucleic acid molecule(s) in the cell to be transfected.
- nucleic acid molecule primarily refers to the physical nucleic acid molecule and the phrase “nucleic acid sequence” primarily refers to the sequence of nucleotides on the nucleic acid molecule, the two phrases can be used interchangeably, especially with respect to a nucleic acid molecule, or a nucleic acid sequence, being capable of encoding a protein.
- recombinant molecule primarily refers to a nucleic acid molecule operatively linked to a transcription control sequence, but can be used interchangeably with the phrase “nucleic acid molecule” which is
- a recombinant nucleic acid molecule includes a recombinant vector, which is any nucleic acid sequence, typically a heterologous sequence, which is operatively linked to the isolated nucleic acid molecule encoding a fusion protein of the present invention, which is capable of enabling recombinant production of the fusion protein, and which is capable of delivering the nucleic acid molecule into a host cell according to the present invention.
- a vector can contain nucleic acid sequences that are not naturally found adjacent to the isolated nucleic acid molecules to be inserted into the vector.
- the vector can be either RNA or DNA, either prokaryotic or eukaryotic, and preferably in the present invention, is a virus or a plasmid.
- Recombinant vectors can be used in the cloning, sequencing, and/or otherwise manipulating of nucleic acid molecules, and can be used in delivery of such molecules (e.g. , as in a DNA composition or a viral vector-based composition).
- Recombinant vectors are preferably used in the expression of nucleic acid molecules, and can also be referred to as expression vectors.
- Preferred recombinant vectors are capable of being expressed in a transfected host cell.
- nucleic acid molecules are operatively linked to expression vectors containing regulatory sequences such as transcription control sequences, translation control sequences, origins of replication, and other regulatory sequences that are compatible with the host cell and that control the expression of nucleic acid molecules of the present invention.
- recombinant molecules of the present invention include nucleic acid molecules that are operatively linked to one or more expression control sequences.
- the phrase "operatively linked” refers to linking a nucleic acid molecule to an expression control sequence in a manner such that the molecule is expressed when transfected (i.e., transformed, transduced or transfected) into a host cell.
- compositions of the invention protect a subject from a pathogenic disease by administering compositions of the invention.
- the phrase "protect a subject", or any permutation thereof can generally refer to preventing a disease, preventing at least one symptom of the disease, delaying onset of a disease, reducing one or more symptoms of the disease, reducing the occurrence of the disease, and/or reducing the severity of the disease.
- the methods of the invention can result in one or more of:
- prevention of the disease or condition prevention of infection, prevention of infection, delay of the onset of disease or symptoms caused by the infection, increased survival, reduction of pathogen burden (e.g., reduction of viral titer), reduction in at least one symptom resulting from the infection in the individual, reduction of organ or physiological system damage resulting from the infection or disease, improvement in organ or system function, and/or improved general health of the individual.
- pathogen burden e.g., reduction of viral titer
- Example 1 is put forth so as to provide those of ordinary skil l in the art with a complete disclosure and description of how to make and use the embodiments, and are not intended to limit the scope of what, the inventors regard as their invention nor are they intended to represent that the experiments below are all or the only experiments performed.
- Example 1 is put forth so as to provide those of ordinary skil l in the art with a complete disclosure and description of how to make and use the embodiments, and are not intended to limit the scope of what, the inventors regard as their invention nor are they intended to represent that the experiments below are all or the only experiments performed.
- Example 1 is put forth so as to provide those of ordinary skil l in the art with a complete disclosure and description of how to make and use the embodiments, and are not intended to limit the scope of what, the inventors regard as their invention nor are they intended to represent that the experiments below are all or the only experiments performed.
- Example 1 is put forth so as to provide those of ordinary skil l in the art with a complete disclosure and description of how to make and use
- mice Female B6, perforin knockout and interleukin 6 knockout mice were obtained from the Jackson Laboratory.
- B6 IL4 reporter (4Get) mice were obtained from Dr R. Locksley (University of California, San Francisco, CA) and BatO knockout mice were obtained from Ken Murphy (Washington University, St Louis, MO). Both these strains were bred at National Jewish Health in a specific-pathogen- free environment. Mice were age-matched within experiments and primed at 6-10 weeks of age.
- OVA protein Sigma
- OVA-peptide or BSA-peptide conjugates were immunized with 10 ⁇ g of OVA protein (Sigma) or OVA-peptide or BSA-peptide conjugates.
- OVA or BSA proteins were conjugated to either 3K peptide or NP peptide as described ( McKee, A.S., et al. 2009. J Immunol 183:4403-4414) using Malemide activated OVA or BSA (Pierce).
- Peptides were supplied by JPT (Berlin, Germany). All immunization were given i.p. and mice were injected with 1 mg of alum (Alydrogel, Brenntag) with or without 10 ⁇ g of MPL
- tetramers made up of the MHC proteins Kb, Db or IAb, bound to antigenic peptides (from ovalbumen, SIINFEKL (SEQ ID NO: 1), or influenza
- nucleoprotein nucleoprotein, NP, or influenza polymerase A protein, PA
- fluorescent proteins allophycocyanin, APC or phycoerythrin, PE
- Splenocytes were removed at the indicated time, a single cell suspension prepared and red blood cells lysed.
- APC-K b /SIINFEKL (SEQ ID NO: 1) tetramer, APC-D b / NP, PE- D b /PA and PE-IA73K tetramer were produced as described (Crawford, F., et al. 1998. Immunity 8:675-682).
- Single cell suspensions were stained with MHC tetramers at 37°C for 2 hours. Antibodies to surface markers were added and the cells incubated for a further 20 minutes at 4°C, except for anti-CCR7 that was also incubated at 37°C for 2 hours.
- Anti-CD 127-PE, anti-CD4 and anti-CD8 APC-Cy7 and streptavidin PeCy7 (BD Biosciences). Anti-B220-pacific blue, anti-F4/80-pacific blue, anti-CD44 PerCP-Cy5.5 and anti-CCRJ biotin were from eBioscience. Anti-CD44 (IM3) Alexa 488, anti-CD122 ( ⁇ 1.4) Alexa 488, anti-class MHC II (Y3P) Alexa 405, anti-IFN- ⁇ (XMG1.2) Alexa 647 were produced in the laboratory at National Jewish Health using Alexa 488, 405 or 657 protein conjugation kits (Molecular Probes). Tetramer+ cells were defined by gating on live (based on forward-side scatter characteristics), CD8 or CD4+ cells that were B220, F4/80, MHC class II negative and either CD4 or CD8 negative respectively.
- mice were perfused to remove blood from the lungs and one lobe cut into small pieces and treated with collagenase and DNase prior to flow staining as described above.
- mice were given drinking water containing 0.8mg/ml of BrdU for 2 days before sacrifice. BrdU+ drinking water was replaced daily and protected from light at all times. Staining was carried out as described (Lenz, D.C., et al. 2004. Proc Natl Acad Sci USA 101 :9357-9362) after the cells had been stained with tetramer and surface antibodies. Anti-BrdU Alexa-488 and Alexa 647 were from Molecular Probes.
- granzyme B staining cells were stained with class I tetramer and surface antibodies then fixed with 4% paraformaldehyde then stained with anti-human granzyme B (BD) for 40 minutes.
- splenocytes were activated ex vivo with 1 ⁇ g/ml SIINFEKL (SEQ ID NO : 1 ) and 1 ⁇ g/ml of Golgi plug (BD Biosciences) for 6 hours. Cells were stained with surface antibodies and then fixed and permeabilized using the BD Cytofix/Cytoperm kit according to manufacturer's
- Antigen specific cytokine was defined as staining above the level of staining from splenocytes cultured in the absence of peptide. Cells were gated on live CD8+ cells that were CD4, B220 and MHC class II negative. In all cases, 2-5 million events were collected on a CyAn ADP (Dakocytomation), and data analyzed using Flow Jo version 8.8 (Treestar). In vivo antibody treatment
- mice were given 200 ⁇ g of anti-PDLl (10F.9G2 from BioXCell) on days 0, 3 and 7 i.p.
- Control antibody was anti-DR5 (HB- 151, grown and purified at N JH) and delivered as for anti-PDL 1.
- a single-cell suspension of B6 splenocytes was prepared and red cell lysed. Half the cells were labeled with 10 ⁇ g/ml SIINFEKL (SEQ ID NO: l) at 37°C for 2 hours, then stained with 1 ⁇ CFSE (Molecular Probes) for 7 minutes at room temperature. The rest of the cells were labeled with 0.05 ⁇ CFSE. Cells were washed and a 1 : Imixture of cells at a total of 5xl0 6 cells injected i.v. into naive or immunized mice. 48 hours later, the percent of CFSE hi out of total CFSE+ cells was measured by flow cytometery.
- TPCK trypsin was added to the diluted supernatant which was plated on confluent MDCK cells. The cells were incubated for 1 hour at 37°C, the supernatants removed, then 1% seakem agar containing media added and plates returned to 37°C. 48 hours later, agar containing neutral red was added and plaques counted after a further 24-36 hours of incubation at 37°C.
- This example illustrates that protein is delivered with alum adjuvant primes CD8 T cells.
- the number and phenotype of antigen specific CD8 T cells activated following immunization of C57BL/6 (B6) with ovalbumin (OVA) protein and alum were determined using K b MHC class I tetramers containing the peptide SIINFEKL (SEQ ID NO: 1) to detect the antigen specific cells by flow cytometry.
- a clear population of activated cells was found in the spleen 8 days after immunization ( Figure 1 A).
- CD8 T cells The priming of CD8 T cells by exogenous antigens occurs by a process called cross-presentation that is thought to be mediated by CD8a+ CDl lc+ dendritic cells (DCs) (Allan, R.S., et al. 2003. Science 301 : 1925-1928; Bevan, M.J. 1976. J Exp Med 143: 1283- 1288).
- DCs dendritic cells
- This example illustrates that alum induces a type 2 response in activated CD4 T cells but a type 1 response in activated CD8 T cells.
- This example illustrates that antigen delivered with alum provides partial protection from influenza virus.
- CD 8 T cells primed with antigen + alum could protect mice from a viral infection
- an epitope from the nucleoprotein of influenza A, NP366- 7 4 ( ⁇ ) was coupled to a protein (OVA, or bovine serum albumin, BSA).
- OVA bovine serum albumin
- BSA bovine serum albumin
- CD8 NP specific cells were confirmed to be primed by staining spleen cells from mice immunized 9 days previously with NP/protein+alum with D b /NP tetramers (Figure 4A). These cells were determined to protect mice from influenza virus challenge. The mice were immunized with NP/protein + alum and then along with control mice, the mice were infected intranasally with influenza A 5-14 weeks after immunization. Mice previously injected with adjuvant alone or immunized with soluble NP/protein lost a significant amount of weight over the first 8 days, then slowly regained some of this weight over the next 12 days. Mice primed with NP/protein + alum, lost less weight
- This example illustrates that MPL enhances cytotoxic differentiation of alum- primed CD8 T cells.
- the combination of adjuvants was determined to be required for the best protection by analysis of the number and effector response of the CD8 T cells.
- the numbers of antigen specific T cells were similar in mice immunized with OVA with either or both adjuvants (Figure 6A), and the numbers of IFNy producing cells were also similar ( Figure 8).
- the number of specific cells markedly declined in mice immunized with OVA+MPL Figure 6A
- the number of NP specific cells dropped below detection levels several weeks after immunization in mice primed with NP/protein+MPL ( Figure 6B).
- Such numbers declined less markedly in animals given antigen + alum or the combination of adjuvants.
- the lack of protection found in mice primed with protein + MPL only was due to the poor generation of long-lived memory cells.
- the number of memory cells generated in response to protein + alum or alum + MPL was similar ( Figure 6A and Figure 6B).
- Alum-generated memory cells were determined to be less effective at protecting mice from challenge ( Figure 4B), as determined by the ability of the primed cells to kill target cells in vivo.
- Immunized mice were injected with peptide-pulsed and non-pulsed splenocytes that could be distinguished since they had been labeled with different intensities of the fluorescent dye,
- T cells primed with OVA + MPL killed the peptide-pulsed target cells very efficiently.
- the addition of alum reduced this killing to some extent, but priming with OVA + alum alone generated CD8 T cells with only limited cytotoxic activity ( Figure 6C and Figure 9).
- IL6 was determined to be required for the enhanced cytotoxic response in the presence of MPL by immunizing wild-type and IL6 knockout mice with OVA delivered with alum or alum + MPL. There was no difference in the number of K b /SIINFEKL (SEQ ID NO: 1) tetramer+ in wild-type or knockout mice immunized with alum or alum + MPL. While there was no difference in the cytotoxic response in mice primed with OVA+alum, the increased killing observed in wild-type mice given both adjuvants was not found in the IL6 knockout mice ( Figure 6D). Therefore, MPL induced IL6 was essential for the efficient differentiation of cytotoxic CD8 T cells.
- Perforin knockout mice were primed with NP/protein + alum + MPL and then infected with influenza A. The wild-type immunized mice were protected, however, the perforin knockout mice lost significant amounts of weight and 4 out 10 had to be sacrificed due to excessive weight loss compared to none in the immunized wild-type group ( Figure 6E).
- This example illustrates that increased PD1 expression on alum-primed CD8 T cells inhibits granzyme B expression and specific killing.
- Alum-primed CD8 T cells were determined to be poor cytotoxic cells due to the T cells expressing inhibitory molecules.
- T cells activated in the presence of alum expressed higher levels PDl ( Figure 7A).
- Co-injection of alum with MPL reduced the expression of PDl on the antigen specific T cells and mice immunized with antigen + MPL had lower levels still ( Figure 7 A and Figure 7B).
- PDl expression declined as the activated cells differentiated into memory cells ( Figure 7B).
- the high expression of PDl on the alum-primed CD8 T cells was determined to inhibit their responses.
- Immunized mice were treated with either an isotype control antibody or anti-PDLl .
- the number of K b /SIINFEKL (SEQ ID NO: 1) tetramer+ T cells primed by immunization with OVA + alum was unaffected by the presence of the anti- PDLl antibody (Figure 7C) as was the production of IFNy by these cells ( Figure 10).
- T cells primed in mice treated with anti-PDLl could kill target cells more effectively ( Figure 7D).
- the high PDl expression on the alum-primed T cells inhibited their ability to kill target cells.
- K b /SIINFEKL (SEQ ID NO : 1 ) tetramer+ T cells from mice primed with OVA + alum expressed granzyme B ex vivo, in contrast either co-immunization with MPL or treatment with anti-PDLl resulted in an increase in the percent of antigen specific T cells that expressed granzyme B (Figure 7E).
- Figure 7E T cells primed in the presence of alum upregulate PDl expression and that this inhibits their differentiation into CTLs.
- the presence of MPL reduces the expression of PDl allowing increased CTL differentiation that can be mimicked by the presence of the anti-PDLl antibody that blocks the interaction between PDl and PDL1.
- Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes. Proc Natl Acad Sci USA 82: 1785-1789.
- Cytotoxic T cells are the predominant players providing cross-protective immunity induced by ⁇ gamma ⁇ - irradiated influenza A viruses. J Virol. 84 (9) 4212.
- Vandepapeliere P., Horsmans, Y., Moris, P., Van Mechelen, M., Janssens, M.,
- Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. Vaccine 26: 1375-1386.
- IL-6 enhances the generation of cytolytic T lymphocytes in the allogeneic mixed leucocyte reaction. Clin Exp Immunol 89: 148-153.
- CD8 single-cell gene coexpression reveals three different effector types present at distinct phases of the immune response. J Exp Med 204: 1193-1205.
- CTL epitopes for influenza A including the H5N1 bird flu; genome-, pathogen-, and HLA-wide screening.
- Lipopeptide vaccines illustrate the potential role of subtype-crossreactive T cells in the control of highly virulent influenza. Influenza Other Respi Viruses 3: 177-182.
- IL-7 regulates basal homeostatic proliferation of antiviral CD4+T cell memory. Proc Natl Acad Sci USA 101 :9357-9362.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/876,089 US20130259898A1 (en) | 2009-11-09 | 2010-11-09 | Vaccine Composition |
AU2010314861A AU2010314861A1 (en) | 2009-11-09 | 2010-11-09 | Vaccine composition |
EP10829286.3A EP2498815A4 (en) | 2009-11-09 | 2010-11-09 | Vaccine composition |
US14/864,081 US20160175431A1 (en) | 2009-11-09 | 2015-09-24 | Vaccine Composition |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25932209P | 2009-11-09 | 2009-11-09 | |
US61/259,322 | 2009-11-09 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/876,089 A-371-Of-International US20130259898A1 (en) | 2009-11-09 | 2010-11-09 | Vaccine Composition |
US14/864,081 Continuation US20160175431A1 (en) | 2009-11-09 | 2015-09-24 | Vaccine Composition |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011057267A1 true WO2011057267A1 (en) | 2011-05-12 |
Family
ID=43970424
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2010/056031 WO2011057267A1 (en) | 2009-11-09 | 2010-11-09 | Vaccine composition |
Country Status (4)
Country | Link |
---|---|
US (2) | US20130259898A1 (en) |
EP (1) | EP2498815A4 (en) |
AU (1) | AU2010314861A1 (en) |
WO (1) | WO2011057267A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011151431A1 (en) * | 2010-06-03 | 2011-12-08 | Glaxosmithkline Biologicals S.A. | Oral vaccine comprising an antigen and a toll-like receptor agonist |
WO2012031140A1 (en) * | 2010-09-01 | 2012-03-08 | Novartis Ag | Adsorption of immunopotentiators to insoluble metal salts |
US9375471B2 (en) | 2012-03-08 | 2016-06-28 | Glaxosmithkline Biologicals Sa | Adjuvanted formulations of booster vaccines |
US9950062B2 (en) | 2009-09-02 | 2018-04-24 | Glaxosmithkline Biologicals Sa | Compounds and compositions as TLR activity modulators |
US10603369B2 (en) | 2011-03-02 | 2020-03-31 | Glaxosmithkline Biologicals Sa | Combination vaccines with lower doses of antigen and/or adjuvant |
WO2021213558A3 (en) * | 2020-04-20 | 2021-12-30 | Centro De Ingenieria Genetica Y Biotecnologia | Viral nucleoprotein and formulations containing same |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007052058A1 (en) | 2005-11-04 | 2007-05-10 | Novartis Vaccines And Diagnostics Srl | Influenza vaccines including combinations of particulate adjuvants and immunopotentiators |
US20080057080A1 (en) * | 2004-05-18 | 2008-03-06 | Vical Incorporated | Influenza virus vaccine composition and methods of use |
US20090181078A1 (en) | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
US20090208531A1 (en) * | 2006-02-16 | 2009-08-20 | National Institutes Of Health Office Of Technology | Antiviral agents and vaccines against influenza |
-
2010
- 2010-11-09 AU AU2010314861A patent/AU2010314861A1/en not_active Abandoned
- 2010-11-09 US US13/876,089 patent/US20130259898A1/en not_active Abandoned
- 2010-11-09 EP EP10829286.3A patent/EP2498815A4/en not_active Withdrawn
- 2010-11-09 WO PCT/US2010/056031 patent/WO2011057267A1/en active Application Filing
-
2015
- 2015-09-24 US US14/864,081 patent/US20160175431A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080057080A1 (en) * | 2004-05-18 | 2008-03-06 | Vical Incorporated | Influenza virus vaccine composition and methods of use |
WO2007052058A1 (en) | 2005-11-04 | 2007-05-10 | Novartis Vaccines And Diagnostics Srl | Influenza vaccines including combinations of particulate adjuvants and immunopotentiators |
US20090208531A1 (en) * | 2006-02-16 | 2009-08-20 | National Institutes Of Health Office Of Technology | Antiviral agents and vaccines against influenza |
US20090181078A1 (en) | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
Non-Patent Citations (86)
Title |
---|
"Remington's Pharmaceutical Sciences", 1990, MACK PUBLISHING CO. |
ALLAN, R.S. ET AL., SCIENCE, vol. 301, 2003, pages 1925 - 1928 |
ALLAN, R.S.; SMITH, C.M.; BELZ, G.T.; VAN LINT, A.L.; WAKIM, L.M.; HEATH, W.R.; CARBONE, F.R.: "Epidermal viral immunity induced by CD8alpha+ dendritic cells but not by Langerhans cells", SCIENCE, vol. 301, 2003, pages 1925 - 1928 |
APPAY, V. ET AL., NAT MED, vol. 14, 2008, pages 623 - 628 |
APPAY, V.; DOUEK, D.C.; PRICE, D.A.: "CD8+ T cell efficacy in vaccination and disease", NAT MED, vol. 14, 2008, pages 623 - 628 |
BARBER, D.L.; WHERRY, E.J.; MASOPUST, D.; ZHU, B.; ALLISON, J.P.; SHARPE, A.H.; FREEMAN, G.J.; AHMED, R.: "Restoring function in exhausted CD8 T cells during chronic viral infection", NATURE, vol. 439, 2006, pages 682 - 687, XP002419629, DOI: doi:10.1038/nature04444 |
BEVAN, M.J., J EXP MED, vol. 143, 1976, pages 1283 - 1288 |
BEVAN, M.J.: "Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay", J EXP MED, vol. 143, 1976, pages 1283 - 1288 |
BOON, A.C. ET AL., J IMMUNOL, vol. 172, 2004, pages 2453 - 2460 |
BOON, A.C.; DE MUTSERT, G.; VAN BAARLE, D.; SMITH, D.J.; LAPEDES, A.S.; FOUCHIER, R.A.; SINTNICOLAAS, K.; OSTERHAUS, A.D.; RIMMELZ: "Recognition of homo- and heterosubtypic variants of influenza A viruses by human CD8+ T lymphocytes", J IMMUNOL, vol. 172, 2004, pages 2453 - 2460 |
BRACIALE, T.J., J EXP MED, vol. 146, 1977, pages 673 - 689 |
BRACIALE, T.J.: "Immunologic recognition of influenza virus-infected cells. II. Expression of influenza A matrix protein on the infected cell surface and its role in recognition by cross-reactive cytotoxic T cells", J EXP MED, vol. 146, 1977, pages 673 - 689 |
BROWN, K.E.; FREEMAN, G.J.; WHERRY, E.J.; SHARPE, A.H.: "Role of PD-1 in regulating acute infections.", CURR OPIN IMMUNOL, vol. 22, 2010, pages 397 - 401, XP027072484, DOI: doi:10.1016/j.coi.2010.03.007 |
CASTELLINO, F.; GERMAIN, R.N.: "Chemokine-guided CD4+ T cell help enhances generation of IL-6RalphahighIL-7Ralpha high prememory CD8+ T cells", J IMMUNOL, vol. 178, 2007, pages 778 - 787 |
CHRISTENSEN, J.P. ET AL., J VIROL, vol. 74, 2000, pages 11690 - 11696 |
CHRISTENSEN, J.P.; DOHERTY, P.C.; BRANUM, K.C.; RIBERDY, J.M.: "Profound protection against respiratory challenge with a lethal H7N7 influenza A virus by increasing the magnitude of CD8(+) T-cell memory", J VIROL, vol. 74, 2000, pages 11690 - 11696 |
CRAWFORD, F. ET AL., IMMUNITY, vol. 8, 1998, pages 675 - 682 |
CRAWFORD, F.; KOZONO, H.; WHITE, J.; MARRACK, P.; KAPPLER, J.: "Detection of antigen-specific T cells with multivalent soluble class II MHC covalent peptide complexes", IMMUNITY, vol. 8, 1998, pages 675 - 682, XP000881127, DOI: doi:10.1016/S1074-7613(00)80572-5 |
DIDIERLAURENT, A.M.; MOREL, S.; LOCKMAN, L.; GIANNINI, S.L.; BISTEAU, M.; CARLSEN, H.; KIELLAND, A.; VOSTERS, O.; VANDERHEYDE, N.;: "AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity", J IMMUNOL, vol. 183, 2009, pages 6186 - 6197, XP055068455, DOI: doi:10.4049/jimmunol.0901474 |
DOHERTY, P.C.; KELSO, A., J CLIN INVEST, vol. 118, 2008, pages 3273 - 3275 |
DOHERTY, P.C.; KELSO, A.: "Toward a broadly protective influenza vaccine", J CLIN INVEST, vol. 118, 2008, pages 3273 - 3275 |
EISENBARTH, S.C.; COLEGIO, O.R.; O'CONNOR, W.; SUTTERWALA, F.S.; FLAVELL, R.A.: "Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants", NATURE, vol. 453, 2008, pages 1122 - 1126 |
EPSTEIN, S.L., J INFECT DIS, vol. 193, 2006, pages 49 - 53 |
EPSTEIN, S.L.: "Prior H1N1 influenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957: an experiment of nature", J INFECT DIS, vol. 193, 2006, pages 49 - 53 |
FRANCHI, L.; NUNEZ, G.: "The Nlrp3 inflammasome is critical for aluminium hydroxide-mediated IL-lbeta secretion but dispensable for adjuvant activity", EUR J IMMUNOL, vol. 38, 2008, pages 2085 - 2089 |
FRANCISCO, L.M.; SAGE, P.T.; SHARPE, A.H.: "The PD-1 pathway in tolerance and autoimmunity.", IMMUNOL REV, vol. 236, 2010, pages 219 - 242, XP002616816, DOI: doi:10.1111/j.1600-065X.2010.00923.x |
FURUYA, Y. ET AL., J VIROL, vol. 84, 2010, pages 4212 - 21 |
FURUYA, Y.; CHAN, J.; REGNER, M.; LOBIGS, M.; KOSKINEN, A.; KOK, T.; MANAVIS, J.; LI, P.; MULLBACHER, A.; ALSHARIFI, M.: "Cytotoxic T cells are the predominant players providing cross-protective immunity induced by {gamma}-irradiated influenza A viruses", J VIROL., vol. 84, no. 9, 2010, pages 4212 |
GALANDRINI, R.; CERNETTI, C.; ALBI, N.; DEMBECH, C.; TERENZI, A.; GRIGNANI, F.; VELARDI, A.: "Interleukin-6 is constitutively produced by human CTL clones and is required to maintain their cytolytic function", CELL IMMUNOL, vol. 138, 1991, pages 11 - 23, XP024007037, DOI: doi:10.1016/0008-8749(91)90128-X |
GIANNINI, S.L.; HANON, E.; MORIS, P.; VAN MECHELEN, M.; MOREL, S.; DESSY, F.; FOURNEAU, M.A.; COLAU, B.; SUZICH, J.; LOSONKSY, G.: "Enhanced humoral and memory B cellular immunity using HPV 16/18 L 1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only", VACCINE, vol. 24, 2006, pages 5937 - 5949 |
HARTY, J.T. ET AL., ANNU REV IMMUNOL, vol. 18, 2000, pages 275 - 308 |
HARTY, J.T.; TVINNEREIM, A.R.; WHITE, D.W.: "CD8+ T cell effector mechanisms in resistance to infection", ANNU REV IMMUNOL, vol. 18, 2000, pages 275 - 308, XP002464044, DOI: doi:10.1146/annurev.immunol.18.1.275 |
HEINY, A.T.; MIOTTO, O.; SRINIVASAN, K.N.; KHAN, A.M.; ZHANG, G.L.; BRUSIC, V.; TAN, T.W.; AUGUST, J.T.: "Evolutionarily conserved protein sequences of influenza a viruses, avian and human, as vaccine targets.", PLOS ONE, vol. 2, 2007, pages E1190 |
HILDNER, K. ET AL., SCIENCE, vol. 322, 2008, pages 1097 - 1100 |
HILDNER, K.; EDELSON, B.T.; PURTHA, W.E.; DIAMOND, M.; MATSUSHITA, H.; KOHYAMA, M.; CALDERON, B.; SCHRAML, B.U.; UNANUE, E.R.; DIA: "Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity", SCIENCE, vol. 322, 2008, pages 1097 - 1100 |
HORNUNG, V. ET AL., NAT IMMUNOL, vol. 9, 2008, pages 847 - 856 |
HORNUNG, V.; BAUERNFEIND, F.; HALLE, A.; SAMSTAD, E.O.; KONO, H.; ROCK, K.L.; FITZGERALD, K.A.; LATZ, E.: "Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization", NAT IMMUNOL, vol. 9, 2008, pages 847 - 856, XP002547009, DOI: doi:10.1038/NI.1631 |
JAMESON, J. ET AL., J IMMUNOL, vol. 162, 1999, pages 7578 - 7583 |
JAMESON, J.; CRUZ, J.; TERAJIMA, M.; ENNIS, F.A.: "Human CD8+ and CD4+ T lymphocyte memory to influenza A viruses of swine and avian species.", J IMMUNOL, vol. 162, 1999, pages 7578 - 7583 |
KEES, U.; KRAMMER, P.H., J EXP MED, vol. 159, 1984, pages 365 - 377 |
KEES, U.; KRAMMER, P.H.: "Most influenza A virus-specific memory cytotoxic T lymphocytes react with antigenic epitopes associated with internal virus determinants", J EXP MED, vol. 159, 1984, pages 365 - 377 |
KOOL, M.; SOULLIE, T.; VAN NIMWEGEN, M.; WILLART, M.A.; MUSKENS, F.; JUNG, S.; HOOGSTEDEN, H.C.; HAMMAD, H.; LAMBRECHT, B.N.: "Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells", J EXP MED., 2008 |
KREIJTZ, J.H.; DE MUTSERT, G.; VAN BAALEN, C.A.; FOUCHIER, R.A.; OSTERHAUS, A.D.; RIMMELZWAAN, G.F.: "Cross-recognition of avian H5N1 influenza virus by human cytotoxic T-lymphocyte populations directed to human influenza A virus", J VIROL, vol. 82, 2008, pages 5161 - 5166 |
LEE, L.Y.; HA DO, L.A.; SIMMONS, C.; DE JONG, M.D.; CHAU, N.V.; SCHUMACHER, R.; PENG, Y.C.; MCMICHAEL, A.J.; FARRAR, J.J.; SMITH,: "Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals", J CLIN INVEST, vol. 118, 2008, pages 3478 - 3490 |
LENZ, D.C. ET AL., PROC NATL ACAD SCI USA, vol. 101, 2004, pages 9357 - 9362 |
LENZ, D.C.; KURZ, S.K.; LEMMENS, E.; SCHOENBERGER, S.P.; SPRENT, J.; OLDSTONE, M.B.; HOMANN, D.: "IL-7 regulates basal homeostatic proliferation of antiviral CD4+T cell memory", PROC NATL ACAD SCI USA, vol. 101, 2004, pages 9357 - 9362 |
LI, H.; WILLINGHAM, S.B.; TING, J.P.; RE, F.: "Cutting edge: inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3", J IMMUNOL, vol. 181, 2008, pages 17 - 21 |
LIN, M.L.; ZHAN, Y.; PROIETTO, A.I.; PRATO, S.; WU, L.; HEATH, W.R.; VILLADANGOS, J.A.; LEW, A.M.: "Selective suicide of cross-presenting CD8+ dendritic cells by cytochrome c injection shows functional heterogeneity within this subset", PROC NATL ACAD SCI USA, vol. 105, 2008, pages 3029 - 3034 |
MARRACK, P.; MCKEE, A.S.; MUNKS, M.W.: "Towards an understanding of the adjuvant action of aluminium", NAT REV IMMUNOL, vol. 9, 2009, pages 287 - 293, XP002719141, DOI: doi:10.1038/nri2510 |
MBOW, M.L.; DE GREGORIO, E.; VALIANTE, N.M.; RAPPUOLI, R.: "New adjuvants for human vaccines.", CURR OPIN IMMUNOL, vol. 22, 2010, pages 411 - 416, XP027072486, DOI: doi:10.1016/j.coi.2010.04.004 |
MCKEE, A.S. ET AL., BMC BIOL, vol. 8, 2010, pages 37 |
MCKEE, A.S. ET AL., J IMMUNOL, vol. 183, 2009, pages 4403 - 4414 |
MCKEE, A.S.; MACLEOD, M.K.; KAPPLER, J.W.; MARRACK, P.: "Immune mechanisms of protection: can adjuvants rise to the challenge?", BMC BIOL, vol. 8, 2010, pages 37, XP021079384, DOI: doi:10.1186/1741-7007-8-37 |
MCKEE, A.S.; MUNKS, M.W.; MACLEOD, M.K.; FLEENOR, C.J.; VAN ROOIJEN, N.; KAPPLER, J.W.; MARRACK, P.: "Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity", J IMMUNOL, vol. 183, 2009, pages 4403 - 4414 |
MCMICHAEL, A.J. ET AL., N ENGL J MED, vol. 309, 1983, pages 13 - 17 |
MCMICHAEL, A.J.; GOTCH, F.M.; NOBLE, G.R.; BEARE, P.A.: "Cytotoxic T-cell immunity to influenza", N ENGL J MED, vol. 309, 1983, pages 13 - 17 |
MING, J.E.; STEINMAN, R.M.; GRANELLI-PIPERNO, A.: "IL-6 enhances the generation of cytolytic T lymphocytes in the allogeneic mixed leucocyte reaction", CLIN EXP IMMUNOL, vol. 89, 1992, pages 148 - 153 |
MOHRS, M.; SHINKAI, K.; MOHRS, K.; LOCKSLEY, R.M.: "Analysis of type 2 immunity in vivo with a bicistronic IL-4 reporter", IMMUNITY, vol. 15, 2001, pages 303 - 311 |
NEWMAN, M.J.; WU, J.Y.; GARDNER, B.H.; MUNROE, K.J.; LEOMBRUNO, D.; RECCHIA, J.; KENSIL, C.R.; COUGHLIN, R.T.: "Saponin adjuvant induction of ovalbumin-specific CD8+ cytotoxic T lymphocyte responses", J IMMUNOL, vol. 148, 1992, pages 2357 - 2362 |
NG, W.C.; GILBERTSON, B.; LIM, B.; ZENG, W.; JACKSON, D.C.; BROWN, L.E.: "Lipopeptide vaccines illustrate the potential role of subtype-crossreactive T cells in the control of highly virulent influenza", INFLUENZA OTHER RESPI VIRUSES, vol. 3, 2009, pages 177 - 182 |
O'NEILL, E. ET AL., J GEN VIROL, vol. 81, 2000, pages 2689 - 2696 |
O'NEILL, E.; KRAUSS, S.L.; RIBERDY, J.M.; WEBSTER, R.G.; WOODLAND, D.L.: "Heterologous protection against lethal A/HongKong/156/97 (H5N1) influenza virus infection in C57BL/6 mice", J GEN VIROL, vol. 81, 2000, pages 2689 - 2696 |
PEIXOTO, A.; EVARISTO, C.; MUNITIC, I.; MONTEIRO, M.; CHARBIT, A.; ROCHA, B.; VEIGA-FERNANDES, H.: "CD8 single-cell gene coexpression reveals three different effector types present at distinct phases of the immune response", JEXP MED, vol. 204, 2007, pages 1193 - 1205 |
PLOTKIN, S.A., CLIN INFECT DIS, vol. 47, 2008, pages 401 - 409 |
PLOTKIN, S.A.: "Vaccines: correlates of vaccine-induced immunity.", CLIN INFECT DIS, vol. 47, 2008, pages 401 - 409, XP055062179, DOI: doi:10.1086/589862 |
POON, L.L.; LEUNG, Y.H.; NICHOLLS, J.M.; PERERA, P.Y.; LICHY, J.H.; YAMAMOTO, M.; WALDMANN, T.A.; PEIRIS, J.S.; PERERA, L.P.: "Vaccinia virus-based multivalent H5N1 avian influenza vaccines adjuvanted with IL-15 confer sterile cross-clade protection in mice", J IMMUNOL, vol. 182, 2009, pages 3063 - 3071 |
RENAULD, J.C.; VINK, A.; VAN SNICK, J.: "Accessory signals in murine cytolytic T cell responses. Dual requirement for IL-1 and IL-6.", J IMMUNOL, vol. 143, 1989, pages 1894 - 1898 |
See also references of EP2498815A4 |
SHEN, L.; ROCK, K.L.: "Priming of T cells by exogenous antigen cross-presented on MHC class I molecules.", CURR OPIN IMMUNOL, vol. 18, 2006, pages 85 - 91, XP025078974, DOI: doi:10.1016/j.coi.2005.11.003 |
SMYTH, M.J.; ORTALDO, J.R.; BERE, W.; YAGITA, H.; OKUMURA, K.; YOUNG, H.A.: "IL-2 and IL-6 synergize to augment the pore-forming protein gene expression and cytotoxic potential of human peripheral blood T cells", J IMMUNOL, vol. 145, 1990, pages 1159 - 1166 |
SURH, C.D.; SPRENT, J., IMMUNITY, vol. 29, 2008, pages 848 - 862 |
SURH, C.D.; SPRENT, J.: "Homeostasis of naive and memory T cells", IMMUNITY, vol. 29, 2008, pages 848 - 862 |
TOPHAM, D.J.; TRIPP, R.A.; DOHERTY, P.C.: "CD8+ T cells clear influenza virus by perforin or Fas-dependent processes", J IMMUNOL, vol. 159, 1997, pages 5197 - 5200 |
TOWNSEND, A.R. ET AL., CELL, vol. 39, 1984, pages 13 - 25 |
TOWNSEND, A.R.; MCMICHAEL, A.J.; CARTER, N.P.; HUDDLESTON, J.A.; BROWNLEE, G.G.: "Cytotoxic T cell recognition of the influenza nucleoprotein and hemagglutinin expressed in transfected mouse L cells", CELL, vol. 39, 1984, pages 13 - 25, XP023911562, DOI: doi:10.1016/0092-8674(84)90187-9 |
ULMER, J.B. ET AL., SCIENCE, vol. 259, 1993, pages 1745 - 1749 |
ULMER, J.B.; DONNELLY, J.J.; PARKER, S.E.; RHODES, G.H.; FELGNER, P.L.; DWARKI, V.J.; GROMKOWSKI, S.H.; DECK, R.R.; DEWITT, C.M.;: "Heterologous protection against influenza by injection of DNA encoding a viral protein", SCIENCE, vol. 259, 1993, pages 1745 - 1749, XP002009751, DOI: doi:10.1126/science.8456302 |
VANDEPAPELIERE, P.; HORSMANS, Y.; MORIS, P.; VAN MECHELEN, M.; JANSSENS, M.; KOUTSOUKOS, M.; VAN BELLE, P.; CLEMENT, F.; HANON, E.: "Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers", VACCINE, vol. 26, 2008, pages 1375 - 1386, XP022492632, DOI: doi:10.1016/j.vaccine.2007.12.038 |
WANG, J. ET AL., J IMMUNOL, vol. 182, 2009, pages 1296 - 1304 |
WANG, J.; OBERLEY-DEEGAN, R.; WANG, S.; NIKRAD, M.; FUNK, C.J.; HARTSHORN, K.L.; MASON, R.J.: "Differentiated human alveolar type II cells secrete antiviral IL-29 (IFN-lambda 1) in response to influenza A infection.", J IMMUNOL, vol. 182, 2009, pages 1296 - 1304, XP002650974 |
WANG, M.; LAMBERTH, K.; HARNDAHL, M.; RODER, G.; STRYHN, A.; LARSEN, M.V.; NIELSEN, M.; LUNDEGAARD, C.; TANG, S.T.; DZIEGIEL, M.H.: "CTL epitopes for influenza A including the H5N1 bird flu; genome-, pathogen-, and HLA-wide screening", VACCINE, vol. 25, 2007, pages 2823 - 2831, XP005939179, DOI: doi:10.1016/j.vaccine.2006.12.038 |
WEBSTER, R.G ET AL., MICROBIOL REV, vol. 56, 1992, pages 152 - 179 |
WEBSTER, R.G.; BEAN, W.J.; GORMAN, O.T.; CHAMBERS, T.M.; KAWAOKA, Y.: "Evolution and ecology of influenza A viruses.", MICROBIOL REV, vol. 56, 1992, pages 152 - 179, XP002555405 |
YEWDELL, J.W. ET AL., PROC NATL ACAD SCI USA, vol. 82, 1985, pages 1785 - 1789 |
YEWDELL, J.W.: "Designing CD8+ T cell vaccines: it's not rocket science (yet", CURR OPIN IMMUNOL, vol. 22, 2010, pages 402 - 410, XP027072485, DOI: doi:10.1016/j.coi.2010.04.002 |
YEWDELL, J.W.; BENNINK, J.R.; SMITH, G.L.; MOSS, B.: "Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes.", PROC NATL ACAD SCI USA, vol. 82, 1985, pages 1785 - 1789 |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9950062B2 (en) | 2009-09-02 | 2018-04-24 | Glaxosmithkline Biologicals Sa | Compounds and compositions as TLR activity modulators |
WO2011151431A1 (en) * | 2010-06-03 | 2011-12-08 | Glaxosmithkline Biologicals S.A. | Oral vaccine comprising an antigen and a toll-like receptor agonist |
WO2012031140A1 (en) * | 2010-09-01 | 2012-03-08 | Novartis Ag | Adsorption of immunopotentiators to insoluble metal salts |
EP2719395A1 (en) * | 2010-09-01 | 2014-04-16 | Novartis AG | Adsorption of immunopotentiators to insoluble metal salts |
US9315530B2 (en) | 2010-09-01 | 2016-04-19 | Novartis Ag | Adsorption of immunopotentiators to insoluble metal salts |
US10098949B2 (en) | 2010-09-01 | 2018-10-16 | Glaxosmithkline Biologicals S.A. | Adsorption of immunopotentiators to insoluble metal salts |
US10603369B2 (en) | 2011-03-02 | 2020-03-31 | Glaxosmithkline Biologicals Sa | Combination vaccines with lower doses of antigen and/or adjuvant |
US9375471B2 (en) | 2012-03-08 | 2016-06-28 | Glaxosmithkline Biologicals Sa | Adjuvanted formulations of booster vaccines |
US9931399B2 (en) | 2012-03-08 | 2018-04-03 | Glaxosmithkline Biologicals Sa | Adjuvanted formulations of booster vaccines |
US10842868B2 (en) | 2012-03-08 | 2020-11-24 | Glaxosmithkline Biologicals Sa | Adjuvanted formulations of booster vaccines |
WO2021213558A3 (en) * | 2020-04-20 | 2021-12-30 | Centro De Ingenieria Genetica Y Biotecnologia | Viral nucleoprotein and formulations containing same |
Also Published As
Publication number | Publication date |
---|---|
EP2498815A1 (en) | 2012-09-19 |
US20130259898A1 (en) | 2013-10-03 |
EP2498815A4 (en) | 2014-03-19 |
AU2010314861A1 (en) | 2012-07-05 |
US20160175431A1 (en) | 2016-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20160175431A1 (en) | Vaccine Composition | |
RU2639551C2 (en) | Computer-optimized antigens with wide reactivity spectrum for influenza viruses of h5n1 and h1n1 | |
JP6874031B2 (en) | Compositions and Methods to Enhance the Immune Response to Eimeria or Limit Eimeria Infections | |
US10059747B2 (en) | Crimean-congo haemorrhagic fever virus antigenic composition | |
EP3888676A1 (en) | Immunogenic combinations | |
ES2748381T3 (en) | CYAA-borne polypeptide (s) and use to induce prophylactic and therapeutic immune responses | |
WO2017165460A9 (en) | Dna antibody constructs and method of using same | |
SA112330950B1 (en) | Recombinant non-pathogenic marek's disease virus constructs | |
US20150150960A1 (en) | Protection against dengue virus and prevention of severe dengue disease | |
CN113454102A (en) | African swine fever vaccine | |
EA018765B1 (en) | Influenza antigen delivery vectors and constructs | |
BR112020020323A2 (en) | VACCINE COMBINATION AND METHOD FOR INDUCING AN IMMUNE RESPONSE. | |
CN104136456A (en) | Computationally optimized broadly reactive antigens for h3n2, h2n2, and b influenza viruses | |
Wang et al. | Combined TLR7/8 and TLR9 ligands potentiate the activity of a Schistosoma japonicum DNA vaccine | |
KR20150130480A (en) | Compositions and methods of enhancing immune responses to enteric pathogens | |
WO2019124557A1 (en) | Cross-immunizing antigen vaccine and method for preparation thereof | |
Liu et al. | Rabies virus lipopeptide conjugated to a TLR7 agonist improves the magnitude and quality of the Th1-biased humoral immune response in mice | |
WO2015136304A1 (en) | Polyamine compounds and uses thereof | |
US20230174588A1 (en) | A vaccine against sars-cov-2 and preparation thereof | |
Stachyra et al. | Highly immunogenic prime–boost DNA vaccination protects chickens against challenge with homologous and heterologous H5N1 virus | |
JP2013506682A (en) | Peptides for inducing a heterologous subtype influenza T cell response | |
Sahin et al. | Assessment of the immunogenicity and protective aspects of a DNA vaccine targeting Crimean Congo hemorrhagic fever virus glycoprotein Gc | |
KR102062624B1 (en) | Vaccine composition for preventing or treating avian influenza and fowl typhoid simultaneouly comprising attenuated Salmonella gallinarum mutant as effective component | |
KR101857705B1 (en) | Use of the PACAP as a molecular adjuvant for vaccines | |
CN108419437B (en) | DNA vaccine for prevention and treatment of HSV-2 infection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10829286 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010314861 Country of ref document: AU Ref document number: 2010829286 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2010314861 Country of ref document: AU Date of ref document: 20101109 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13876089 Country of ref document: US |